Types of recurrence | ER -vs.+ | PR -vs.+ | Her-2 +vs.- | p53 +vs.- |
---|
 | N | HR (95% CI) |
P
| N | HR (95% CI) |
P
| N | HR (95% CI) |
P
| N | HR (95% CI) |
P
|
---|
Overall | 5 | 1.21 (0.96, 1.53)a | 0.107 | 4 | 1.29 (0.94, 1.76)a | 0.118 | 7 | 1.97 (1.41, 2.75)a | <0.01 | 4 | 1.78 (1.49, 2.12)a | <0.01 |
Local recurrence | 5 | 1.21 (0.96, 1.53)a | 0.107 | 4 | 1.29 (0.94, 1.76)a | 0.118 | 6 | 1.93 (1.34, 2.78)a | <0.01 | 3 | 1.73 (1.44, 2.07)a | <0.01 |
Distant recurrence | 0 | - | - | 0 | - | - | 1 | 2.17 (0.99, 4.75) | - | 1 | 2.57 (1.30, 5.06) | - |
Recurrence | 0 | - | - | 0 | - | - | 1 | 1.57 (1.26, 1.97) | - | 1 | 1.83 (1.10, 3.02) | - |
- Local recurrence is defined to include true recurrence (TR), local failure (LF), local recurrence or relapse (LR), ipsilateral breast tumor recurrence (IBTR), locoregional recurrence (LRR), or second ipsilateral breast cancer (SIBC). Distant recurrence is defined to include distant metastasis (DM) or distant failure (DF). Recurrence is defined to include any local and/or distant recurrence, which is the merge of LR and DR in the same study or not definitely mentioned.
- aThe HRs and 95% CIs of enrolled studies are pooled by the fixed-effects model.
- CI, confidence interval; ER, estrogen receptor; Her-2, human epidermal growth factor receptor 2; HR, hazard ratio; N, number of studies; PR, progesterone receptor.